Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.51
MACK's Cash to Debt is ranked lower than
87% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. MACK: 0.51 )
Ranked among companies with meaningful Cash to Debt only.
MACK' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 2.45 Max: No Debt
Current: 0.51
Equity to Asset -1.13
MACK's Equity to Asset is ranked lower than
97% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. MACK: -1.13 )
Ranked among companies with meaningful Equity to Asset only.
MACK' s Equity to Asset Range Over the Past 10 Years
Min: -4.85  Med: -0.71 Max: 0.24
Current: -1.13
-4.85
0.24
F-Score: 3
Z-Score: -6.39
M-Score: -0.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -135.48
MACK's Operating margin (%) is ranked lower than
56% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. MACK: -135.48 )
Ranked among companies with meaningful Operating margin (%) only.
MACK' s Operating margin (%) Range Over the Past 10 Years
Min: -2220.11  Med: -236.36 Max: -64.48
Current: -135.48
-2220.11
-64.48
Net-margin (%) -158.49
MACK's Net-margin (%) is ranked lower than
58% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. MACK: -158.49 )
Ranked among companies with meaningful Net-margin (%) only.
MACK' s Net-margin (%) Range Over the Past 10 Years
Min: -2284.59  Med: -231.54 Max: -81.06
Current: -158.49
-2284.59
-81.06
ROA (%) -99.45
MACK's ROA (%) is ranked lower than
88% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. MACK: -99.45 )
Ranked among companies with meaningful ROA (%) only.
MACK' s ROA (%) Range Over the Past 10 Years
Min: -110.9  Med: -75.22 Max: -47.47
Current: -99.45
-110.9
-47.47
ROC (Joel Greenblatt) (%) -665.63
MACK's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. MACK: -665.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MACK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1458.87  Med: -732.80 Max: -468.88
Current: -665.63
-1458.87
-468.88
Revenue Growth (3Y)(%) 6.10
MACK's Revenue Growth (3Y)(%) is ranked higher than
55% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. MACK: 6.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MACK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -33.65 Max: 6.1
Current: 6.1
0
6.1
EBITDA Growth (3Y)(%) -2.40
MACK's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. MACK: -2.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MACK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -43.75 Max: -2.4
Current: -2.4
EPS Growth (3Y)(%) 2.00
MACK's EPS Growth (3Y)(%) is ranked higher than
59% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. MACK: 2.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MACK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -42.65 Max: 2
Current: 2
0
2
» MACK's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MACK Guru Trades in Q2 2015

Jim Simons 17,113 sh (New)
Murray Stahl 19,000 sh (unchged)
Joel Greenblatt Sold Out
» More
Q3 2015

MACK Guru Trades in Q3 2015

Murray Stahl 25,000 sh (+31.58%)
Jim Simons Sold Out
» More
Q4 2015

MACK Guru Trades in Q4 2015

Murray Stahl 25,000 sh (unchged)
» More
Q1 2016

MACK Guru Trades in Q1 2016

Paul Tudor Jones 17,800 sh (New)
Jim Simons 636,613 sh (New)
Murray Stahl 25,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MACK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:PACB, NAS:CASC, NAS:INSM, NAS:ANIP, NAS:CERS, NAS:INO, NAS:NTLA, OTCPK:BPMUF, NAS:XNCR, OTCPK:GNFTF, NAS:ANIK, NAS:ATRA, OTCPK:IPHYF, NAS:FOLD, NAS:CORT, OTCPK:SNBIF, NAS:KERX, OTCPK:BIESF, NAS:ZIOP, NAS:DVAX » details
Traded in other countries:MP6.Germany,
Merrimack Pharmaceuticals Inc is engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer.

Merrimack Pharmaceuticals Inc was incorporated in 1993 and reincorporated in the state of Delaware in October 2010. The Company is engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer. It faces competition from specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. The Company is subject to rules and regulations from the federal, state and local authorities.

Ratios

vs
industry
vs
history
P/S 6.57
MACK's P/S is ranked higher than
69% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. MACK: 6.57 )
Ranked among companies with meaningful P/S only.
MACK' s P/S Range Over the Past 10 Years
Min: 1.78  Med: 9.53 Max: 16.67
Current: 6.57
1.78
16.67
EV-to-EBIT -6.57
MACK's EV-to-EBIT is ranked lower than
99.99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. MACK: -6.57 )
Ranked among companies with meaningful EV-to-EBIT only.
MACK' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.4  Med: -6.80 Max: -0.5
Current: -6.57
-20.4
-0.5
EV-to-EBITDA -6.82
MACK's EV-to-EBITDA is ranked lower than
99.99% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. MACK: -6.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
MACK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.4  Med: -7.05 Max: -0.5
Current: -6.82
-21.4
-0.5
Current Ratio 1.65
MACK's Current Ratio is ranked lower than
81% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. MACK: 1.65 )
Ranked among companies with meaningful Current Ratio only.
MACK' s Current Ratio Range Over the Past 10 Years
Min: 0.69  Med: 2.08 Max: 4.51
Current: 1.65
0.69
4.51
Quick Ratio 1.57
MACK's Quick Ratio is ranked lower than
78% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. MACK: 1.57 )
Ranked among companies with meaningful Quick Ratio only.
MACK' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 2.06 Max: 4.51
Current: 1.57
0.69
4.51
Days Inventory 1.00
MACK's Days Inventory is ranked higher than
98% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. MACK: 1.00 )
Ranked among companies with meaningful Days Inventory only.
MACK' s Days Inventory Range Over the Past 10 Years
Min: 14746.79  Med: 14746.79 Max: 14746.79
Current: 1
Days Sales Outstanding 59.64
MACK's Days Sales Outstanding is ranked higher than
53% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. MACK: 59.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
MACK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.77  Med: 67.32 Max: 300.77
Current: 59.64
11.77
300.77
Days Payable 5.00
MACK's Days Payable is ranked lower than
88% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. MACK: 5.00 )
Ranked among companies with meaningful Days Payable only.
MACK' s Days Payable Range Over the Past 10 Years
Min: 0.82  Med: 16.89 Max: 40062.72
Current: 5
0.82
40062.72

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.69
MACK's Price/Median PS Value is ranked higher than
71% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. MACK: 0.69 )
Ranked among companies with meaningful Price/Median PS Value only.
MACK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.19  Med: 1.06 Max: 1.41
Current: 0.69
0.19
1.41
Earnings Yield (Greenblatt) (%) -15.21
MACK's Earnings Yield (Greenblatt) (%) is ranked lower than
63% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. MACK: -15.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MACK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -17.16  Med: 0.00 Max: 0
Current: -15.21
-17.16
0

More Statistics

Revenue (TTM) (Mil) $95.70
EPS (TTM) $ -1.33
Beta2.21
Short Percentage of Float25.98%
52-Week Range $5.02 - 11.18
Shares Outstanding (Mil)127.73

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 166 245 342
EPS ($) -0.71 -0.19 0.22
EPS w/o NRI ($) -0.71 -0.19 0.22
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MACK

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Starbucks Corp, KD Supply Holdings Inc, Capital One Financial Corp, Merr Dec 14 2014 

More From Other Websites
Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union Jul 25 2016
Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union Jul 25 2016
ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of... Jul 25 2016
Merrimack Announces Timing of Second Quarter 2016 Investor Conference Call Jul 19 2016
Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold Jul 13 2016
Merrimack Stock Up on Fast Track Status for Seribantumab Jul 07 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer Jul 06 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer Jul 06 2016
Buy 5 Attractive Biotechs at Bargain Prices Jul 05 2016
NAPOLI-1 Data Demonstrates ONIVYDE® Regimen Maintains Quality of Life While Improving Overall... Jun 30 2016
NAPOLI-1 Data Demonstrates ONIVYDE® Regimen Maintains Quality of Life While Improving Overall... Jun 30 2016
The Quest for an Effective Treatment for Pancreatic Cancer Jun 22 2016
Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in... Jun 21 2016
Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on... Jun 21 2016
Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on... Jun 21 2016
MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 16 2016
Merrimack Announces Positive Data on Oncology Candidate Jun 07 2016
Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in... Jun 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)